WO2016120828A1 - Traitement du cancer du sein par un antagoniste de m-csf - Google Patents

Traitement du cancer du sein par un antagoniste de m-csf Download PDF

Info

Publication number
WO2016120828A1
WO2016120828A1 PCT/IB2016/050442 IB2016050442W WO2016120828A1 WO 2016120828 A1 WO2016120828 A1 WO 2016120828A1 IB 2016050442 W IB2016050442 W IB 2016050442W WO 2016120828 A1 WO2016120828 A1 WO 2016120828A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
csf
antibody
effective amount
therapeutically effective
Prior art date
Application number
PCT/IB2016/050442
Other languages
English (en)
Inventor
Wolfgang Hackl
Masato Murakami
Marion Wiesmann
Yan JI
Marie-Louise FJAELLSKOG
Keith Wharton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2016120828A1 publication Critical patent/WO2016120828A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7153—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons or colony-stimulating factors [CSF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

L'invention concerne, en partie, une méthode de traitement d'un patient porteur d'un cancer du sein, comprenant l'administration au patient d'une quantité thérapeutiquement efficace d'un antagoniste de M-CSF, en se basant sur le fait que le niveau d'expression du CD163 du patient permet de prédire que le patient répondra à un antagoniste de M-CSF. L'invention concerne, en partie, une méthode de traitement d'un patient porteur d'un cancer du sein triple négatif, comprenant l'administration au patient d'une quantité thérapeutiquement efficace d'un anticorps contre M-CSF ou d'un fragment de ce dernier, l'anticorps ou fragment contre M-CSF comprenant 1, 2, 3, 4, 5, ou 6 CDRs tel que présenté dans le Tableau 1. L'invention concerne, en partie, une méthode de traitement d'un patient porteur d'un cancer du sein, comprenant l'administration de l'association d'une quantité thérapeutiquement efficace d'un antagoniste de M-CSF, d'une quantité thérapeutiquement efficace d'un deuxième agent et d'une quantité thérapeutiquement efficace d'un troisième agent.
PCT/IB2016/050442 2015-01-30 2016-01-28 Traitement du cancer du sein par un antagoniste de m-csf WO2016120828A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109893P 2015-01-30 2015-01-30
US62/109,893 2015-01-30

Publications (1)

Publication Number Publication Date
WO2016120828A1 true WO2016120828A1 (fr) 2016-08-04

Family

ID=55405377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/050442 WO2016120828A1 (fr) 2015-01-30 2016-01-28 Traitement du cancer du sein par un antagoniste de m-csf

Country Status (2)

Country Link
TW (1) TW201632202A (fr)
WO (1) WO2016120828A1 (fr)

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1992019244A2 (fr) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede de traitement des maladies respiratoires infectieuses
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5399331A (en) 1985-06-26 1995-03-21 The Liposome Company, Inc. Method for protein-liposome coupling
US5416016A (en) 1989-04-03 1995-05-16 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
WO1997032572A2 (fr) 1996-03-04 1997-09-12 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5679377A (en) 1989-11-06 1997-10-21 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1997044013A1 (fr) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Particules legeres aerodynamiques pour la diffusion de medicaments dans l'appareil respiratoire
WO1998031346A1 (fr) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1999015154A1 (fr) 1997-09-24 1999-04-01 Alkermes Controlled Therapeutics, Inc. Procedes de fabrication de preparations de liberation controlee a base de polymere
WO1999020253A1 (fr) 1997-10-23 1999-04-29 Bioglan Therapeutics Ab Procede d'encapsulage
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (fr) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6316024B1 (en) 1996-10-11 2001-11-13 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6350466B1 (en) 1994-08-05 2002-02-26 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO2003028752A1 (fr) 2001-10-03 2003-04-10 The University Of Queensland Immunomodulation du csf-1
US20050059113A1 (en) 2003-09-10 2005-03-17 Vahe Bedian Antibodies to M-CSF
WO2005068503A2 (fr) 2004-01-07 2005-07-28 Chiron Corporation Anticorps monoclonal specifique du m-csf et ses utilisations
US20090117103A1 (en) 2005-03-08 2009-05-07 Pharmacia & Upjohn Company Llc M-CSF Antibody compositions Having Reduced Levels of Endotoxin

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5399331A (en) 1985-06-26 1995-03-21 The Liposome Company, Inc. Method for protein-liposome coupling
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5416016A (en) 1989-04-03 1995-05-16 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5679377A (en) 1989-11-06 1997-10-21 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1992019244A2 (fr) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede de traitement des maladies respiratoires infectieuses
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6350466B1 (en) 1994-08-05 2002-02-26 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
WO1997032572A2 (fr) 1996-03-04 1997-09-12 The Penn State Research Foundation Materiaux et procedes permettant d'accroitre la penetration intracellulaire
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1997044013A1 (fr) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Particules legeres aerodynamiques pour la diffusion de medicaments dans l'appareil respiratoire
US6316024B1 (en) 1996-10-11 2001-11-13 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998031346A1 (fr) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999015154A1 (fr) 1997-09-24 1999-04-01 Alkermes Controlled Therapeutics, Inc. Procedes de fabrication de preparations de liberation controlee a base de polymere
WO1999020253A1 (fr) 1997-10-23 1999-04-29 Bioglan Therapeutics Ab Procede d'encapsulage
WO1999066903A2 (fr) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
WO2003028752A1 (fr) 2001-10-03 2003-04-10 The University Of Queensland Immunomodulation du csf-1
US20050059113A1 (en) 2003-09-10 2005-03-17 Vahe Bedian Antibodies to M-CSF
WO2005068503A2 (fr) 2004-01-07 2005-07-28 Chiron Corporation Anticorps monoclonal specifique du m-csf et ses utilisations
US20090117103A1 (en) 2005-03-08 2009-05-07 Pharmacia & Upjohn Company Llc M-CSF Antibody compositions Having Reduced Levels of Endotoxin

Non-Patent Citations (84)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS, pages: 6.3.1 - 6.3.6
"Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms, 19th ed.,", 1995, MACK PUB. CO.
"Vinayak ASCO", ASCO ANNUAL MEETING J CLIN ONCOL, vol. 32, 2014, pages 5S
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 17, 1997, pages 3389 - 3402
ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 77
AVIS, ET AL.: "Pharmaceutical Dosage Forms: Parenteral Medications", 1993, MARCEL DEKKER
BACH: "Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases", 1993, MARCEL DEKKER
BAERT ET AL., NEW ENGL. J. MED., vol. 348, 2003, pages 601 - 608
BENIAMINOVITZ ET AL., NEW ENGL. J. MED., vol. 342, 2000, pages 613 - 619
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BLOEMAN, FEBS LETT., vol. 357, 1995, pages 140
BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
BUTT, W. R., E: "Practical Immunology", 1984, MARCEL DEKKER
CERRETTI ET AL., MOLECULAR IMMUNOLOGY, vol. 25, 1988, pages 761
CHABNER AND LONGO: "Cancer Chemotherapy and Biotherapy", 2001, LIPPINCOTT, WILLIAMS & WILKINS
CHAVEZ KATHRYN J ET AL: "Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.", BREAST DISEASE 2010, vol. 32, no. 1-2, 2010, pages 35 - 48, XP002712389, ISSN: 1558-1551 *
CHIRGWIN ET AL., BIOCHEMISTRY, 1979, pages 5294 - 5299
DENT: "Good Laboratory and Good Clinical Practice", 2001, URCH PUBL.
DULAC, CURR. TOP. DEV. BIOL., vol. 36, 1998, pages 245
DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692
GENNARO: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS, AND WILKINS
GHOSH ET AL., NEW ENGL. J. MED., vol. 348, 2003, pages 24 - 32
GILBERT, J., CLIN. CANCER. RES., vol. 12, 2006, pages 1794 - 1803
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
GREEN; DUFFULL, BR J CLIN PHARMACOL, vol. 58, no. 2, 2004, pages 119 - 133
GRINDEY, G. ET AL., CANCER INVEST., vol. 8, no. 2, 1990, pages 313
HAMILTON ET AL., METHODS, vol. 70, 2014, pages 59 - 73
HAMILTON J, A., IMMUNO TODAY., vol. 18, no. 7, 1997, pages 313 - 7
HAMILTON J. A., J LEUKOC BIOL., vol. 62, no. 2, 1997, pages 145 - 55
HARDMAN ET AL.,: "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10.sup.th ed.,", 2001, MCGRAW-HILL
HARDMAN ET AL.: "Goodman and Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL
HELD ET AL., GENOME RESEARCH, vol. 6, 1996, pages 986 - 994
HEROLD ET AL., NEW ENGL. J. MED., vol. 346, 2002, pages 1692 - 1698
HOWARD ET AL., J. NEUROSURG., vol. 7 1, 1989, pages 105
HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034
J. J. KILLION; I. J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273
JENA ET AL., J. IMMUNOL. METHODS, vol. 190, 1996, pages 199
K. KEINANEN; M. L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 68
KAWASAKI ET AL., SCIENCE, vol. 230, 1985, pages 291
KRESINA: "Monoclonal Antibodies, Cytokines and Arthritis", 1991, MARCEL DEKKER
LADNER ET AL., EMBO JOURNAL, vol. 6, 1987, pages 2693
LANGER AND WISE: "Medical Applications of Controlled Release", 1974, CRC PRES
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LEHMANN, J CLIN INVEST, vol. 121, no. 7, 2011, pages 2750 - 67
LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190
LIEBERMAN, ET AL.: "Pharmaceutical Dosage Forms: Disperse Systems", 1990, MARCEL DEKKER
LIEBERMAN, ET AL.: "Pharmaceutical Dosage Forms: Tablets", 1990, MARCEL DEKKER
LIPSKY ET AL., NEW ENGL. J. MED., vol. 343, 2000, pages 1594 - 1602
LIU ET AL., J. NEUROL. NEUROSURG. PSYCH., vol. 67, 1999, pages 451 - 456
MAHMOUD, J CLIN PATHOL, vol. 65, 2012, pages 159 - 163
MARKMAN, M. ET AL., J. CLIN. ONCOL., vol. 17, no. 4, 1999, pages 1141
MAYNARD ET AL.: "A Handbook of SOPs for Good Clinical Practice", 1996, INTERPHARM PRESS
MCEVOY, GK,: "American Hospital Formulary Service Drug Information", 2000, AMERICAN SOCIETY OF HEALTH SYSTEM
MILGROM ET AL., NEW ENGL. J. MED., vol. 341, 1999, pages 1966 - 1973
MULRANE ET AL., EXPERT REV MOL DIAGN, vol. 8, no. 6, 2008, pages 707 - 725
MYERS; MILLER, CABIOS, 1989
OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER, vol. 39, 1995, pages 180
PANDIT ET AL., SCIENCE, vol. 258, 1992, pages 1358 - 62
PAULUS PATRICK ET AL: "Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.", CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 4349 - 4356, XP055149182, ISSN: 0008-5472 *
POOLE AND PETERSON: "Pharmacotherapeutics for Advanced Practice:A Practical Approach", 2001, LIPPINCOTT, WILLIAMS & WILKINS
PORTIELJI ET AL., CANCER IMMUNOL. IMMUNOTHER, vol. 52, 2003, pages 133 - 144
RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685
RANGER; PEPPAS, J. MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", vol. 3, 1989, COLD SPRING HARBOR LABORATORY, article "Chapter 18,"
SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574
SCHREIER, J. BIOL. CHEM., vol. 269, 1994, pages 9090
SEFTON, CRC CRIT. REF BIOMED. ENG., vol. 14, 1987, pages 20
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556
SLAMON ET AL., NEW ENGL. J. MED., vol. 344, 2001, pages 783 - 792
SMOLEN AND BALL: "Controlled Drug Bioavailability, Drug Product Design and Performance", 1984, WILEY
SWIERCZAK AGNIESZKA ET AL: "The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor.", CANCER IMMUNOLOGY RESEARCH AUG 2014, vol. 2, no. 8, August 2014 (2014-08-01), pages 765 - 776, XP002755689, ISSN: 2326-6074 *
UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038
WANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 9717
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WAWRZYNCZAK: "Antibody Therapy", 1996, BIOS SCIENTIFIC PUB. LTD
WEINER; KOTKOSKIE: "Excipient Toxicity and Safety", 2000, MARCEL DEKKER, INC.
YANG ET AL., NEW ENGL. J. MED., vol. 349, 2003, pages 427 - 434
YUAN, ONCOTARGETS AND THERAPY, vol. 7, 2014, pages 1475 - 1480

Also Published As

Publication number Publication date
TW201632202A (zh) 2016-09-16

Similar Documents

Publication Publication Date Title
JP6564408B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
JP7048319B2 (ja) 癌のための治療方法及び診断方法
JP2023036582A (ja) がんのための治療方法及び診断方法
KR102389677B1 (ko) Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US20180369269A1 (en) Antibodies that specifically block the biological activity of a tumor antigen
JP2020527351A (ja) がんの治療法及び診断法
JP2016105096A (ja) バイオマーカー及び治療の方法
TW201837467A (zh) 用於癌症之診斷及治療方法
KR20160092992A (ko) 암 바이오마커 및 이의 용도
KR20140064971A (ko) c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
KR20160137599A (ko) C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
KR20230118713A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
KR20190095921A (ko) 항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
TW201511770A (zh) 診斷及治療肝癌之組合物及方法
JP2021534195A (ja) 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置
WO2015107171A1 (fr) Méthodes d'identification de patients souffrant d'un cancer du foie pour lesquels un traitement avec un anticorps anti-fgfr4 antagoniste est plus à même d'être bénéfique
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
EP2984108B1 (fr) Anticorps anti-s100a7 pour le traitement et le diagnostic de cancer
TW202015730A (zh) 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
WO2016120828A1 (fr) Traitement du cancer du sein par un antagoniste de m-csf
WO2020181080A1 (fr) Biomarqueurs pour le traitement du cancer
WO2014140330A1 (fr) Anticorps d'internalisation anti-ddr1 et leur utilisation médicale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16705817

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16705817

Country of ref document: EP

Kind code of ref document: A1